ATAI News and Press, ATAI Life Sciences N.V. From 11/29/23

2023-11-29 18:55:54 ET Summary ATAI Life Sciences is a biopharmaceutical company focused on developing psychedelic-based treatments for mental health conditions. The company has a diverse portfolio of drug candidates in various clinical trial phases, showing promising results. ...

It is estimated that at least 57 million individuals in America have a mental-health condition. Of this number, roughly 14 million suffer from serious mental issues. Despite these huge numbers, conventional treatments aren’t effective for a significant number of patients, which has promp...

2023-11-28 09:20:00 ET November 28, 2023 (Investorideas.com Newswire) investorideas.com, a global news source covering leading sectors including marijuana and psychedelic stocks releases a special edition of the top rated Investor Ideas potcast (Cannabis Podcast). In today's episode...

Johns Hopkins University recently held a congressional briefing series that was attended by experts from different fields, including policymakers as well as members of the public. During the briefings, associate professor Matthew Eisenberg posited that treatment with psychedelic substances in...

Psychedelics have been subject to significantly increased attention from the medical and scientific communities in recent years due to claims of their medical efficacy against various mental health conditions. While a majority of psychedelic compounds are still illegal at the federal level and in...

2023-11-14 07:28:21 ET More on ATAI Life Sciences Atai Life Sciences: RL-007, Targeting Schizophrenia Subpopulation With No FDA Approved Therapies Psychedelic drugs market to break $7B in 2029 led by these 3 meds Psychedelics research amendments advance in House comm...

Phase 2b study of RL-007 in CIAS patients continues to be on track to report data in 2H 2024 and data from the EMP-01 (MDMA derivative) Phase 1 study is anticipated to report out later this year. Phase 1 data of VLS-01 (a proprietary oral transmucosal film formulation of DMT) demonstrated...

Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...

ATAI Life Sciences N.V. (ATAI) is expected to report $-0.2 for Q3 2023

Individuals who take part in ayahuasca ceremonies regularly reported fewer chronic and lifestyle-related diseases, increased physical activity, better diets and improved well-being compared to the general population. A recent study from the Netherlands has found that regular ayahuasca ceremony ...